Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2017 - 2026)

Ascendis Pharma A has disclosed Non-Current Deffered Revenue across 10 years of filings, most recently posting $2.0 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $2.0 million, up 147.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 147.63% YoY), and the FY2025 annual result was $5.8 million, up 7.71% from the prior year.
• Non-Current Deffered Revenue came in at $2.0 million for Q1 2026 at Ascendis Pharma A, down from $5.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $14.5 million in Q4 2022 to a low of -$7.6 million in Q4 2023.
• The 5-year median for Non-Current Deffered Revenue is $3.3 million (2022), against an average of $3.2 million.
• Across the five-year window, Non-Current Deffered Revenue surged 31140.24% in 2022 and sank 313.19% in 2025, its largest moves.
• Ascendis Pharma A's Non-Current Deffered Revenue stood at $14.5 million in 2022, then slumped by 152.53% to -$7.6 million in 2023, then soared by 170.14% to $5.3 million in 2024, then advanced by 7.71% to $5.8 million in 2025, then tumbled by 64.7% to $2.0 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $2.0 million (Q1 2026), $5.8 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.